TransMedics Group, Inc. (TMDX): Price and Financial Metrics

TransMedics Group, Inc. (TMDX): $61.90

-2.39 (-3.72%)

POWR Rating

Component Grades














  • TMDX scores best on the Growth dimension, with a Growth rank ahead of 88.78% of US stocks.
  • The strongest trend for TMDX is in Stability, which has been heading down over the past 177 days.
  • TMDX ranks lowest in Quality; there it ranks in the 7th percentile.

TMDX Stock Summary

  • With a price/sales ratio of 27.54, TRANSMEDICS GROUP INC has a higher such ratio than 95.01% of stocks in our set.
  • With a year-over-year growth in debt of 93.21%, TRANSMEDICS GROUP INC's debt growth rate surpasses 87.48% of about US stocks.
  • As for revenue growth, note that TMDX's revenue has grown 154.25% over the past 12 months; that beats the revenue growth of 94.56% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to TRANSMEDICS GROUP INC, a group of peers worth examining would be SPIR, APP, PAR, BASE, and LAW.
  • TMDX's SEC filings can be seen here. And to visit TRANSMEDICS GROUP INC's official web site, go to

TMDX Valuation Summary

  • In comparison to the median Healthcare stock, TMDX's price/sales ratio is 472% higher, now standing at 28.6.
  • Over the past 44 months, TMDX's EV/EBIT ratio has gone down 28.8.

Below are key valuation metrics over time for TMDX.

Stock Date P/S P/B P/E EV/EBIT
TMDX 2022-12-02 28.6 10.9 -48.7 -49.9
TMDX 2022-12-01 27.5 10.5 -46.7 -47.7
TMDX 2022-11-30 27.5 10.5 -46.8 -47.8
TMDX 2022-11-29 25.9 9.9 -44.0 -44.8
TMDX 2022-11-28 26.0 9.9 -44.2 -45.0
TMDX 2022-11-25 26.4 10.1 -44.8 -45.7

TMDX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TMDX has a Quality Grade of D, ranking ahead of 12.13% of graded US stocks.
  • TMDX's asset turnover comes in at 0.2 -- ranking 143rd of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows TMDX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.200 0.677 -0.179
2021-03-31 0.162 0.659 -0.164
2020-12-31 0.179 0.649 -0.186
2020-09-30 0.183 0.646 -0.227
2020-06-30 0.202 0.609 -0.280
2020-03-31 0.243 0.610 -0.314

TMDX Price Target

For more insight on analysts targets of TMDX, see our TMDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $53.00 Average Broker Recommendation 1.5 (Moderate Buy)

TMDX Stock Price Chart Interactive Chart >

Price chart for TMDX

TMDX Price/Volume Stats

Current price $61.90 52-week high $64.36
Prev. close $64.29 52-week low $10.00
Day low $61.33 Volume 294,900
Day high $64.29 Avg. volume 329,921
50-day MA $49.67 Dividend yield N/A
200-day MA $36.47 Market Cap 1.98B

TransMedics Group, Inc. (TMDX) Company Bio

TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.

TMDX Latest News Stream

Event/Time News Detail
Loading, please wait...

TMDX Latest Social Stream

Loading social stream, please wait...

View Full TMDX Social Stream

Latest TMDX News From Around the Web

Below are the latest news stories about TRANSMEDICS GROUP INC that investors may wish to consider to help them evaluate TMDX as an investment opportunity.

TransMedics (TMDX) is a Great Momentum Stock: Should You Buy?

Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Yahoo | November 17, 2022

TransMedics Group Third Quarter 2022 Earnings: Beats Expectations

TransMedics Group ( NASDAQ:TMDX ) Third Quarter 2022 Results Key Financial Results Revenue: US$25.7m (up 378% from 3Q...

Yahoo | November 9, 2022

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on November 2, 2022, TransMedics granted non-qualified stock options to purchase an aggregate of 138,400 shares of its common stock to six employees as a material inducement for each employee's entry into employment with TransMedics. The options were approved by the Compensation Committe

Yahoo | November 7, 2022

TransMedics Group (NASDAQ:TMDX) shareholder returns have been stellar, earning 230% in 3 years

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Yahoo | November 6, 2022

Morgan Stanley Remains a Hold on TransMedics Group (TMDX)

E ratio of -26.33.

Austin Angelo on TipRanks | November 4, 2022

Read More 'TMDX' Stories Here

TMDX Price Returns

1-mo 10.61%
3-mo 14.12%
6-mo 128.41%
1-year 180.73%
3-year 225.28%
5-year N/A
YTD 223.07%
2021 -3.72%
2020 4.68%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7434 seconds.